<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278211</url>
  </required_header>
  <id_info>
    <org_study_id>PREFFIR</org_study_id>
    <nct_id>NCT02278211</nct_id>
  </id_info>
  <brief_title>Prediction of Recurrent Events With 18F-Fluoride</brief_title>
  <acronym>PREFFIR</acronym>
  <official_title>Prediction of Recurrent Events With 18F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients With Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Grampian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre observational study. It will make use of the positron emission
      tomography (PET) tracer 18F-sodium fluoride (18F-NaF) as a marker of coronary plaque
      vulnerability to detect culprit and non-culprit unstable coronary plaques in patients with
      recent myocardial infarctions. The investigators will then perform long-term follow-up of
      these patients to determine the prognostic significance of coronary 18F-NaF uptake
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to recruit 700 patients hospitalised with myocardial infarction and
      proven multivessel coronary artery disease. All patients will undergo a combined CT coronary
      angiogram (CTCA) and PET scan using 18F-NaF as a tracer. Patients will then have clinical
      follow-up before undergoing a repeat CTCA at 2 years to assess progression of coronary
      disease. Clinical review of all patients will continue until study completion (given 2 years
      of recruitment this is likely to last 4 years) and following this the investigators will
      continue to monitor for further cardiovascular events via review of patient electronic health
      records for a further 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death or non-fatal recurrent myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent major adverse cardiac events defined as cardiac death, recurrent myocardial infarction, and rehospitalization for acute coronary syndrome, unscheduled coronary revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilization of patients with and without focal 18F-NaF uptake in coronary plaques unrelated to index myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>Whether the presence of 18F-NaF uptake in non-culprit plaques is related to increased healthcare resource utilisation over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each individual component end-point of the composite end-point of major adverse cardiac event</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18F-NaF uptake localisation to culprit plaque causing the index myocardial infarction</measure>
    <time_frame>3 weeks</time_frame>
    <description>Whether 18F-NaF uptake localises to the culprit plaque responsible for the index myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Territory of subsequent myocardial reinfarction in patients with focal 18F-NaF uptake in coronary plaques unrelated to index myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>Whether there is detectable 18F-NaF uptake in coronary plaques which are not the culprit related to the index MI but are potentially the cause of subsequent MI as determined by the territory of the subsequent MI corresponding with myocardium supplied by the artery with initial 18F-NaF uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery plaque progression by computed tomography coronary angiography. Plaque volume, composition and calcification</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Study Cohort</arm_group_label>
    <description>Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recent (&lt;21 days) type 1 myocardial infarction and multi-vessel coronary
        artery disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged ≥50 years with recent (&lt;21 days) type 1 myocardial infarction and
             angiographically proven multi-vessel coronary artery disease defined as at least two
             major epicardial vessels with any combination of either (a) &gt;50% luminal stenosis, or
             (b) previous revascularization (percutaneous coronary intervention or coronary artery
             bypass graft surgery).

          2. Provision of informed consent prior to any study specific procedures

        Exclusion Criteria:

          1. Inability or unwilling to give informed consent

          2. Women who are pregnant, breastfeeding or of child-bearing potential (women who have
             experienced menarche, are pre-menopausal and have not been sterilised) will not be
             enrolled into the trial

          3. Major intercurrent illness with life expectancy &lt;2 year

          4. Renal dysfunction (estimated glomerular filtration rate ≤30 mL/min/1.73 m2)

          5. Contraindication to iodinated contrast agent, positron emission tomography or computed
             tomography

          6. Atrial fibrillation

          7. Previous recruitment into the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Newby, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Adamson, MBChB</last_name>
    <phone>01312426364</phone>
    <email>philip.adamson@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Newby, PhD</last_name>
    <phone>01312426515</phone>
    <email>d.e.newby@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Edinburgh Heart Centre</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip D. Adamson, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014 Feb 22;383(9918):705-13. doi: 10.1016/S0140-6736(13)61754-7. Epub 2013 Nov 11.</citation>
    <PMID>24224999</PMID>
  </reference>
  <reference>
    <citation>Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48. doi: 10.1016/j.jacc.2011.12.037.</citation>
    <PMID>22516444</PMID>
  </reference>
  <reference>
    <citation>Mohler ER 3rd, Alavi A, Wilensky RL. (18)F-fluoride imaging for atherosclerosis. J Am Coll Cardiol. 2012 Oct 23;60(17):1711-2; author reply p.1712-3. doi: 10.1016/j.jacc.2012.06.038.</citation>
    <PMID>23079119</PMID>
  </reference>
  <reference>
    <citation>Derlin T, Tóth Z, Papp L, Wisotzki C, Apostolova I, Habermann CR, Mester J, Klutmann S. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med. 2011 Jul;52(7):1020-7. doi: 10.2967/jnumed.111.087452. Epub 2011 Jun 16.</citation>
    <PMID>21680686</PMID>
  </reference>
  <reference>
    <citation>Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010 Jun;51(6):862-5. doi: 10.2967/jnumed.110.076471. Epub 2010 May 19.</citation>
    <PMID>20484438</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

